70 related articles for article (PubMed ID: 9088589)
1. Effect of the non peptide angiotensin II antagonist, GR117289C on the vasoconstrictor actions of angiotensin II in the human forearm.
Lyons D; Webster J; Nixon A; Young MM; Smith J; Benjamin N
Br J Clin Pharmacol; 1997 Mar; 43(3):323-6. PubMed ID: 9088589
[TBL] [Abstract][Full Text] [Related]
2. Selective AT1 receptor antagonism enhances sympathetically mediated vasoconstriction in man.
Lyons D; Jackson SH; Swift CG
Clin Pharmacol Ther; 2007 Jan; 81(1):83-7. PubMed ID: 17186003
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic and pharmacokinetic properties of an angiotensin II receptor antagonist--characterization by use of Schild regression technique in man.
Breithaupt-Grögler K; Malerczyk C; Belz GG; Butzer R; Herrmann V; Stass H; Wensing G
Int J Clin Pharmacol Ther; 1997 Oct; 35(10):434-41. PubMed ID: 9352392
[TBL] [Abstract][Full Text] [Related]
4. The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects.
Morgan JM; Palmisano M; Piraino A; Hirschhorn W; Spencer S; Prasad PP; Ortiz M; Lloyd P
Clin Pharmacol Ther; 1997 Jan; 61(1):35-44. PubMed ID: 9024172
[TBL] [Abstract][Full Text] [Related]
5. The angiotensin II receptor antagonist valsartan inhibits endothelin 1-induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein beta3 subunit (GNB3) C825T polymorphism.
Mitchell A; Rushentsova U; Siffert W; Philipp T; Wenzel RR
Clin Pharmacol Ther; 2006 Mar; 79(3):274-81. PubMed ID: 16513451
[TBL] [Abstract][Full Text] [Related]
6. Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors.
Rehman A; Rahman AR; Rasool AH
J Hum Hypertens; 2002 Apr; 16(4):261-6. PubMed ID: 11967720
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of vasoconstriction by angiotensin receptor antagonist GR117289C in arterial grafts.
Liu MH; Floten HS; Furnary AP; Yim AP; He GW
Ann Thorac Surg; 2000 Dec; 70(6):2064-9. PubMed ID: 11156121
[TBL] [Abstract][Full Text] [Related]
8. The effect of HN-65021 on responses to angiotensin II in human forearm vasculature.
Cockcroft JR; Chowienczyk PJ; Brett SE; Mant TG; Durnin C; Lynn F; Stevenson P; Ritter JM
Br J Clin Pharmacol; 1995 Dec; 40(6):591-3. PubMed ID: 8703667
[TBL] [Abstract][Full Text] [Related]
9. Effects of the angiotensin type I receptor antagonist, losartan, on systemic and regional vascular responses to lower body negative pressure in healthy volunteers.
Duranteau J; Pussard E; Berdeaux A; Giudicelli JF
Br J Clin Pharmacol; 1995 Nov; 40(5):431-8. PubMed ID: 8703646
[TBL] [Abstract][Full Text] [Related]
10. Statin therapy increases vascular sensitivity to angiotensin II in hypercholesterolaemic patients.
Sim JS; Dick JB; Struthers AD
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):109-13. PubMed ID: 15526245
[TBL] [Abstract][Full Text] [Related]
11. Urotensin II evokes potent vasoconstriction in humans in vivo.
Böhm F; Pernow J
Br J Pharmacol; 2002 Jan; 135(1):25-7. PubMed ID: 11786476
[TBL] [Abstract][Full Text] [Related]
12. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm.
Cockcroft JR; Sciberras DG; Goldberg MR; Ritter JM
J Cardiovasc Pharmacol; 1993 Oct; 22(4):579-84. PubMed ID: 7505360
[TBL] [Abstract][Full Text] [Related]
13. Effects of losartan on vasoconstrictor responses to angiotensin II in the forearm vascular bed of healthy volunteers.
Baan J; Chang PC; Vermeij P; Pfaffendorf M; van Zwieten PA
Cardiovasc Res; 1996 Nov; 32(5):973-9. PubMed ID: 8944829
[TBL] [Abstract][Full Text] [Related]
14. Effect of eprosartan on catecholamines and peripheral haemodynamics in subjects with insulin-induced hypoglycaemia.
Christensen M; Ibsen H; Worck R
Clin Sci (Lond); 2005 Feb; 108(2):113-9. PubMed ID: 15383007
[TBL] [Abstract][Full Text] [Related]
15. The effects of candesartan on vascular responses to angiotensin II and norepinephrine in normal volunteers.
Tran D; Phoon S; Howes L
J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2(3):199-203. PubMed ID: 11881123
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection.
Rongen GA; Smits P; Ver Donck K; Willemsen JJ; De Abreu RA; Van Belle H; Thien T
J Clin Invest; 1995 Feb; 95(2):658-68. PubMed ID: 7860749
[TBL] [Abstract][Full Text] [Related]
17. Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding.
Maillard MP; Rossat J; Brunner HR; Burnier M
J Pharmacol Exp Ther; 2000 Nov; 295(2):649-54. PubMed ID: 11046101
[TBL] [Abstract][Full Text] [Related]
18. [Activation of the renin-angiotensin system and blood pressure variability in rats].
Blanc J; Lambert G; Elghozi JL
Arch Mal Coeur Vaiss; 2000 Aug; 93(8):1019-22. PubMed ID: 10989749
[TBL] [Abstract][Full Text] [Related]
19. The effects of angiotensin II on pulse wave velocity in healthy humans.
Rehman A; Rahman AR; Rasool AH; Naing NN
Int J Clin Pharmacol Ther; 2001 Oct; 39(10):423-30. PubMed ID: 11680667
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin AT1 receptor blockade abolishes the reflex sympatho-excitatory response to adenosine.
Rongen GA; Brooks SC; Ando Si; Abramson BL; Floras JS
J Clin Invest; 1998 Feb; 101(4):769-76. PubMed ID: 9466971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
